Article
Clinical Neurology
Simone Quintana, Marco Russo, Gian Camillo Manzoni, Paola Torelli
Summary: This observational study compares the efficacy, safety, and impact of anti-CGRP monoclonal antibodies on additional parameters such as disability in social, family, and work activities.
NEUROLOGICAL SCIENCES
(2022)
Article
Clinical Neurology
Marcella Curone, Vincenzo Tullo, Henri Albert Didier, Gennaro Bussone
Summary: Monoclonal antibodies inhibiting CGRP are effective in reducing monthly headache days in migraine patients with medication overuse headache.
NEUROLOGICAL SCIENCES
(2022)
Article
Clinical Neurology
Luigi Francesco Iannone, Davide Fattori, Silvia Benemei, Alberto Chiarugi, Pierangelo Geppetti, Francesco De Cesaris
Summary: This study evaluated the effects of discontinuation and retreatment of anti-CGRP mAbs in resistant chronic migraine patients and found that most patients experienced worsening of symptoms during the 3-month discontinuation period, which was rapidly resolved by retreatment. However, a quarter of patients showed sustained benefit during discontinuation and did not require retreatment.
EUROPEAN JOURNAL OF NEUROLOGY
(2022)
Article
Medicine, General & Internal
Ciro De Luca, Filippo Baldacci, Sonia Mazzucchi, Irene Lombardo, Letizia Curto, Martina Ulivi, Lucia Chico, Michele Papa, Gabriele Siciliano, Sara Gori
Summary: The study demonstrates that targeted antibodies against CGRP and its receptor are effective tools for treating high-frequency resistant migraine and medication-overuse headache. The treatment shows precocious effects with high individual responder rates, significantly improving biological and clinical features.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Neurosciences
Adisa Kuburas, Bianca N. Mason, Benjamin Hing, Anne-Sophie Wattiez, Alyssa S. Reis, Levi P. Sowers, Cristina Moldovan Loomis, Leon F. Garcia-Martinez, Andrew F. Russo
Summary: CGRP and PACAP have emerged as mediators of migraine, inducing migraine-like symptoms through independent pathways in mice. Monoclonal antibodies targeting PACAP may be effective in patients unresponsive to CGRP-based therapeutics.
JOURNAL OF NEUROSCIENCE
(2021)
Review
Biotechnology & Applied Microbiology
Jose Maria Serra Lopez-Matencio, Ana Beatriz Gago-Veiga, Manuel Gomez, Estefania Alanon Plaza, Gina Paola Mejia, Miguel Angel Gonzalez-Gay, Santos Castaneda
Summary: In recent years, a new class of drugs, anti-CGRP monoclonal antibodies, has been developed for migraine therapy. These drugs target CGRP, a key player in the pathogenesis of migraine, and have led to exciting possibilities in migraine treatment. However, there is still a lack of experience in managing these drugs and challenges in identifying suitable patients for treatment.
EXPERT OPINION ON BIOLOGICAL THERAPY
(2022)
Article
Pharmacology & Pharmacy
Lorenzo Cantarelli, Diana Pestana Grafina, Amanda Gonzalez Perez, Sara Garcia Gil, Fernando Gutierrez Nicolas, Emma Ramos Santana, Marco Antonio Navarro Davila, Sheila Maria Otazo Perez, Gloria Calzado Gomez, Sergio Perez Reyes, Gloria Julia Nazco Casariego
Summary: The study confirms the effectiveness and safety of drugs targeting the calcitonin gene-related peptide receptor (CGRPr) in real clinical practice for chronic migraine patients. However, there is little benefit from erenumab intensification compared to the standard dose, with similar effectiveness but worse tolerability.
ANNALS OF PHARMACOTHERAPY
(2023)
Article
Clinical Neurology
Peter McAllister, Paul K. Winner, Jessica Ailani, Dawn C. Buse, Richard B. Lipton, George Chakhava, Mette Krog Josiassen, Annika Lindsten, Lahar Mehta, Anders Ettrup, Roger Cady
Summary: This study investigated the impact of Eptinezumab, a preventive migraine treatment, on patient-reported headache impact, acute medication optimization, and perception of disease change. The results showed that patients treated with Eptinezumab experienced significant improvement in headache impact after 4 weeks compared to placebo, particularly in patients reporting headache pain freedom at 2 hours after treatment initiation.
JOURNAL OF HEADACHE AND PAIN
(2022)
Article
Clinical Neurology
Roger Cady, Richard B. Lipton, Dawn C. Buse, Mette Krog Josiassen, Annika Lindsten, Anders Ettrup
Summary: Treatment with eptinezumab was associated with improvements in acute medication optimization and reductions in headache impact, particularly in those with poor acute treatment optimization prior to preventive treatment with eptinezumab.
JOURNAL OF HEADACHE AND PAIN
(2022)
Article
Clinical Neurology
Magdalena Nowaczewska, Marcin Straburzynski, Marta Waliszewska-Prosol, Grzegorz Meder, Joanna Janiak-Kiszka, Wojciech Kazmierczak
Summary: This study aimed to investigate the relationship between baseline clinical parameters and cerebral blood flow (CBF) with the efficacy of monoclonal antibodies (mAbs). The study found that patients with lower baseline mean blood flow velocity (Vm) in the cerebral arteries had a better response to mAbs treatment. Additionally, unilateral pain localization, higher HIT-6 scores, and absence of family history of migraine were associated with better responsiveness to mAbs.
FRONTIERS IN NEUROLOGY
(2022)
Article
Clinical Neurology
Modar Khalil, David Moreno-Ajona, Maria Dolores Villar-Martinez, Fiona Greenwood, Jan Hoffmann, Peter J. Goadsby
Summary: Our study evaluated the efficacy and tolerability of erenumab in managing chronic migraine in a tertiary care setting. The results showed significant reduction in monthly migraine days and overall improvement in other variables at 3 months. More than half of the patients experienced a clinically meaningful improvement in migraine days. No serious adverse events were reported.
EUROPEAN JOURNAL OF NEUROLOGY
(2022)
Article
Clinical Neurology
Anna P. Andreou, Matteo Fuccaro, Bethany Hill, Madeleine Murphy, Valeria Caponnetto, Rachael Kilner, Giorgio Lambru
Summary: This study analyzed the long-term sustained effectiveness of erenumab in treating resistant chronic migraine. The findings revealed that only a minority of patients maintained good efficacy over a period of two years. However, erenumab can still provide relief in terms of reducing migraine load and related disability in some patients.
JOURNAL OF HEADACHE AND PAIN
(2022)
Article
Medicine, General & Internal
Zaira Maraia, Diletta Ricci, Marco Bruno Luigi Rocchi, Alessandro Moretti, Celestino Bufarini, Arturo Cavaliere, Manola Peverini
Summary: The study retrospectively researched the efficacy of Erenumab's treatment, confirming its effectiveness in preventing episodic and chronic migraine with a success rate of 96% in the analyzed cases.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Clinical Neurology
Roberta Noseda, Francesca Bedussi, Claudio Gobbi, Chiara Zecca, Alessandro Ceschi
Summary: The study assessed the safety profile of erenumab, galcanezumab, and fremanezumab during pregnancy and lactation. Although no specific maternal toxicities or major birth defects were found, continuous surveillance is necessary due to the limited number of reported adverse reactions and lack of long-term safety data.
Article
Clinical Neurology
Charlotte Ernstsen, Sarah L. Christensen, Rikke H. Rasmussen, Brian S. Nielsen, Inger Jansen-Olesen, Jes Olesen, David M. Kristensen
Summary: Using in vivo and ex vivo models, the study shows that PACAP-38 can provoke migraine-like changes independently of CGRP and partially through K-ATP channels. The findings suggest that PACAP-38 antagonism could be a potential alternative therapeutic approach for patients non-responsive to CGRP-targeting therapies.
Review
Pharmacology & Pharmacy
Enrico Bentivegna, Michelangelo Luciani, Valeria Ferrari, Silvia Galastri, Francesco Baldari, Francesco Scarso, Piera A. Lamberti, Paolo Martelletti
Summary: This article provides a narrative review of the scientific evidence on recently approved and emerging drugs for the prophylactic treatment of migraines. Monoclonal antibodies targeting the CGRP signaling pathway have brought innovation to prophylactic migraine therapy. New classes of molecules such as gepants and ditans show exceptional results. Additionally, new prophylactic drugs with various targets are emerging. These therapies will enhance migraine management and provide personalized medicine for each patient.
EXPERT OPINION ON PHARMACOTHERAPY
(2022)
Article
Environmental Sciences
Farzaneh Allahdinian Hesaruiyeh, Saeed Rajabi, Mohadeseh Motamed-Jahromi, Mohammad Sarhadi, Michelle L. Bell, Razieh Khaksefidi, Somayeh Sarhadi, Leili Mohammadi, Kamal Dua, Amin Mohammadpour, Paolo Martelletti
Summary: This study aimed to evaluate the levels of lead (Pb), 8-hydroxy di-guanine (8-oxo-Gua), and malondialdehyde (MDA) in the blood serum of opium addicts and non-addicts. The results showed that the amount of Pb in the blood serum of addicts was significantly higher than non-addicts, but there were no significant differences in the levels of 8-oxo-Gua and MDA between the two groups.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
(2022)
Editorial Material
Clinical Neurology
William David Wells-Gatnik, Fidel Dominique Festin Ambat, Paolo Martelletti
EXPERT REVIEW OF NEUROTHERAPEUTICS
(2022)
Article
Clinical Neurology
Claudia Altamura, R. Ornello, F. Ahmed, A. Negro, A. M. Miscio, A. Santoro, A. Alpuente, A. Russo, M. Silvestro, S. Cevoli, N. Brunelli, L. Grazzi, C. Baraldi, S. Guerzoni, A. P. Andreou, G. Lambru, I Frattale, K. Kamm, R. Ruscheweyh, M. Russo, P. Torelli, E. Filatova, N. Latysheva, A. Gryglas-Dworak, M. Straburzynski, C. Butera, B. Colombo, M. Filippi, P. Pozo-Rosich, P. Martelletti, S. Sacco, F. Vernieri
Summary: This study aimed to investigate the outcome of OnabotulinumtoxinA (OBT-A) as preventative therapy in elderly chronic migraine (CM) patients. The results showed that there were no differences in the primary and secondary endpoints between elderly and non-elderly patients in the first three treatment cycles.
JOURNAL OF NEUROLOGY
(2023)
Article
Geriatrics & Gerontology
Dilara Onan, William David Wells-Gatnik, Enrico Bentivegna, Christian Lampl, Paolo Martelletti
Summary: Migraine is a prevalent and burdensome disease, affecting around 14% of the global population. Recent randomized controlled trials (RCTs) of new migraine drugs have included participants aged over 65 years, providing clinicians with safety and efficacy data for treating older patients. However, the inclusion criteria of RCTs often exclude patients with multiple comorbidities, reducing the clinical applicability of the new drugs for older patients.
Article
Clinical Neurology
Dilara Onan, Ozlem Ulger, Paolo Martelletti
Summary: This study aimed to compare the effects of telerehabilitation and face-to-face rehabilitation on patients with chronic nonspecific neck pain (CNNP). The results showed that both methods were equally effective in improving neck functional capacity, reducing pain and disability.
EXPERT REVIEW OF NEUROTHERAPEUTICS
(2023)
Review
Biochemistry & Molecular Biology
Claudio Tana, David Garcia Azorin, Francesco Cinetto, Cesare Mantini, Marco Tana, Massimo Caulo, Fabrizio Ricci, Paolo Martelletti, Francesco Cipollone, Maria Adele Giamberardino
Summary: Migraine and sarcoidosis may share some common biological and clinical pathways. Both conditions involve inflammation and immune system dysregulation. Migraine is a common comorbidity in sarcoidosis patients, and there have been reports of individuals with neurosarcoidosis experiencing migraines. The exact relationship between the two disorders is still unclear.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Editorial Material
Health Care Sciences & Services
Christina Deligianni, Paolo Martelletti, Dimos D. Mitsikostas
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH
(2023)
Article
Clinical Neurology
Elena Gross, Elena Ruiz de la Torre, Paolo Martelletti
Summary: Despite the evidence on the epidemiology of migraine and its impact on patients in terms of disability, burden, and cost, the stigma of migraine has not been fully acknowledged as a key factor in the chronicity of the disease and social isolation of patients. In this commentary, a European advocacy body and a clinician specializing in migraine present different perspectives, highlighting the need for actions to improve community perception and propose treatment and rehabilitation paths for the reintegration of migraine sufferers into social contexts.
NEUROLOGY AND THERAPY
(2023)
Review
Biochemistry & Molecular Biology
Tsubasa Takizawa, Keiko Ihara, Shunsuke Uno, Seiya Ohtani, Narumi Watanabe, Noboru Imai, Jin Nakahara, Satoko Hori, David Garcia-Azorin, Paolo Martelletti
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY
(2023)
Article
Pharmacology & Pharmacy
William Wells-Gatnik, Paolo Martelletti
Summary: A recent study has found an increased risk of neurodevelopmental disorders in individuals exposed to valproate or topiramate. Regulatory bodies are reviewing the safety of topiramate during pregnancy. This review highlights the concerns regarding the use of valproate and topiramate in women of childbearing potential.
EXPERT OPINION ON DRUG SAFETY
(2023)
Review
Pharmacology & Pharmacy
William David Wells-Gatnik, Tiffany Yazmin Wences Chirino, Fatma Nur Onan, Dilara Onan, Paolo Martelletti
Summary: This article introduces new drugs for the treatment of migraine and discusses their clinical trial outcomes. As approximately 50% of patients do not respond to calcitonin gene-related peptide therapies, there is significant value in future drug innovation. Overall, these emerging drugs are largely developed based on important targets of migraine pathogenesis, but the clinical value of individual drugs needs further research to appropriately target the relevant pathways.
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2023)
Article
Medicine, General & Internal
Antonio Martocchia, Cinzia Piccoli, Michele Fortunato Notarangelo, Daniela Sergi, Beata Ostrowska, Paolo Martelletti, Carmine Savoia, Luciano De Biase, Giorgio Sesti
Summary: The use of point-of-care ultrasound for evaluating left ventricle systolic function (LV EF) has shown high accuracy in this study. It can support the diagnosis of heart failure in emergency situations without delays.
INTERNAL AND EMERGENCY MEDICINE
(2023)
Article
Clinical Neurology
C. F. Mullins, M. Fuccaro, D. Pang, L. Min, A. P. Andreou, G. Lambru
Summary: A single infusion of IV lidocaine may be an effective and safe transitional treatment for refractory headache conditions with facial pain and trigeminal neuralgia. The sustained effect of repeated treatment cycles in some patients may suggest a role as long-term preventive therapy in some patients.
FRONTIERS IN NEUROLOGY
(2023)
Article
Clinical Neurology
Arife Cimen Atalar, Ayse Nur Ozdag Acarli, Betuel Baykan, Paolo Martelletti, Hayrunnisa Bolay, Mustafa Ertas, Esme Ekizoglu, Omer Karadas, Burcu Polat, Isil Yazici Gencdal, David Garcia Azorin, Dimos Mitsikostas, Loukia Apostolakopoulou, Hamit Genc, Pinar Yalinay Dikmen, Esra Aciman Demirel, Elif Ilgaz Aydinlar, Rabia Gokcen Gozubatik-Celik, Javid Shafiyev, Bahar Tasdelen, Aynur Ozge
Summary: This multinational observational study aimed to investigate prolonged or worsened headaches associated with COVID-19 vaccination. Questionnaires were used to assess the vaccination-related headaches at three time points. Repeated K-means cluster analysis identified patient profiles with prolonged or worsened headaches related to COVID-19 vaccination.
JOURNAL OF HEADACHE AND PAIN
(2023)